MX366341B - Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer. - Google Patents
Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer.Info
- Publication number
- MX366341B MX366341B MX2015017609A MX2015017609A MX366341B MX 366341 B MX366341 B MX 366341B MX 2015017609 A MX2015017609 A MX 2015017609A MX 2015017609 A MX2015017609 A MX 2015017609A MX 366341 B MX366341 B MX 366341B
- Authority
- MX
- Mexico
- Prior art keywords
- peptidomimetics
- peptides
- treatments
- cancer patient
- combination uses
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000000816 peptidomimetic Substances 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000010261 cell growth Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000012820 cell cycle checkpoint Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dermatology (AREA)
Abstract
La presente invención se refiere a compuestos que incluyen péptidos y peptidomiméticos que se pueden usar para tratar trastornos proliferativos, tales como los asociados con células de tumores benignos y malignos. Mientras la invención no se limita a ningún mecanismo particular, los compuestos de la invención pretenden funcionar al menos parcialmente inhibiendo el punto de control del Ciclo celular G2. Entonces, los compuestos de la invención se pueden usar para inhibir solo el crecimiento celular o se puede usar en combinación con un tratamiento de daño de ácido nucleico para inhibir el crecimiento celular.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361838777P | 2013-06-24 | 2013-06-24 | |
| PCT/IB2014/001579 WO2014207556A1 (en) | 2013-06-24 | 2014-06-24 | Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015017609A MX2015017609A (es) | 2016-04-15 |
| MX366341B true MX366341B (es) | 2019-07-05 |
Family
ID=52141164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015017609A MX366341B (es) | 2013-06-24 | 2014-06-24 | Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9221872B2 (es) |
| EP (1) | EP3013351B1 (es) |
| JP (1) | JP6401255B2 (es) |
| KR (1) | KR102247493B1 (es) |
| CN (1) | CN105324121A (es) |
| AU (1) | AU2014300713B2 (es) |
| BR (1) | BR112015032542A2 (es) |
| CA (1) | CA2916136C (es) |
| CL (1) | CL2015003704A1 (es) |
| CY (1) | CY1122523T1 (es) |
| DK (1) | DK3013351T3 (es) |
| ES (1) | ES2765300T3 (es) |
| HR (1) | HRP20192264T1 (es) |
| HU (1) | HUE046873T2 (es) |
| IL (1) | IL243266B (es) |
| LT (1) | LT3013351T (es) |
| MX (1) | MX366341B (es) |
| MY (1) | MY182232A (es) |
| PH (1) | PH12015502855B1 (es) |
| PL (1) | PL3013351T3 (es) |
| PT (1) | PT3013351T (es) |
| RS (1) | RS60180B1 (es) |
| RU (1) | RU2732440C2 (es) |
| SG (1) | SG11201510490VA (es) |
| SI (1) | SI3013351T1 (es) |
| WO (1) | WO2014207556A1 (es) |
| ZA (1) | ZA201600089B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| KR102236829B1 (ko) | 2013-03-15 | 2021-04-07 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | 헵시딘 유사체 및 이의 용도 |
| AU2015258863B2 (en) | 2014-05-16 | 2019-10-24 | Protagonist Therapeutics, Inc. | Alpha4beta7 integrin thioether peptide antagonists |
| AU2015289642B2 (en) | 2014-07-17 | 2021-02-25 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| EP3201217A4 (en) | 2014-10-01 | 2018-07-18 | Protagonist Therapeutics Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| WO2016054411A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| TWI805542B (zh) * | 2015-10-23 | 2023-06-21 | 日商坎巴斯有限公司 | 用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合 |
| US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| EP3432906A4 (en) | 2016-03-23 | 2020-04-01 | Protagonist Therapeutics, Inc. | METHOD FOR SYNTHETIZING ALPHA4BETA7 PEPTIDE ANTAGONISTS |
| HRP20220479T1 (hr) | 2016-06-01 | 2022-05-27 | Athira Pharma, Inc. | Spojevi |
| US10278957B2 (en) | 2017-09-11 | 2019-05-07 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| EP3749345A4 (en) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
| TW202019948A (zh) | 2018-07-12 | 2020-06-01 | 美商領導醫療有限公司 | 介白素-23受體之肽抑制劑及其治療發炎疾病之用途 |
| MX2022000397A (es) | 2019-07-10 | 2022-04-25 | Protagonist Therapeutics Inc | Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| CN118063554A (zh) | 2020-01-15 | 2024-05-24 | 詹森生物科技公司 | 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途 |
| KR20220141808A (ko) | 2020-01-15 | 2022-10-20 | 얀센 바이오테크 인코포레이티드 | 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도 |
| KR20230110570A (ko) | 2020-11-20 | 2023-07-24 | 얀센 파마슈티카 엔.브이. | 인터류킨-23 수용체의 펩티드 억제제의 조성물 |
| TW202330013A (zh) | 2021-07-14 | 2023-08-01 | 美商健生生物科技公司 | 介白素－２３受體之脂化肽抑制劑 |
| CN115804834B (zh) * | 2021-08-10 | 2025-10-21 | 昆明医科大学 | 一种具有提高免疫力和抗肿瘤以及延长寿命的多肽及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100863090B1 (ko) * | 2002-01-17 | 2008-10-13 | 다케다 파머수티컬 컴패니 리미티드 | 항증식 활성을 지니고／지니거나 핵산 손상제 또는 처리제를 증강시키는 펩티드 및 펩티드모방체 |
| EP1556398B1 (en) * | 2002-10-31 | 2009-09-09 | Metabasis Therapeutics, Inc. | Novel cytarabine monophosphate prodrugs |
| US7125842B2 (en) * | 2003-04-07 | 2006-10-24 | Canbas Co. Ltd. | Anti-fungal compounds and methods of use |
| CN1812805A (zh) * | 2003-06-25 | 2006-08-02 | 坎巴斯有限公司 | 具有免疫调节活性、抗炎活性和抗病毒活性的肽和肽模仿物 |
| PE20091924A1 (es) | 2008-05-14 | 2010-01-04 | Takeda Pharmaceutical | Compuesto peptidico y su uso |
-
2014
- 2014-06-24 AU AU2014300713A patent/AU2014300713B2/en active Active
- 2014-06-24 JP JP2016520755A patent/JP6401255B2/ja active Active
- 2014-06-24 CA CA2916136A patent/CA2916136C/en active Active
- 2014-06-24 EP EP14818523.4A patent/EP3013351B1/en active Active
- 2014-06-24 PT PT148185234T patent/PT3013351T/pt unknown
- 2014-06-24 RU RU2016101718A patent/RU2732440C2/ru active
- 2014-06-24 BR BR112015032542A patent/BR112015032542A2/pt not_active Application Discontinuation
- 2014-06-24 HR HRP20192264TT patent/HRP20192264T1/hr unknown
- 2014-06-24 WO PCT/IB2014/001579 patent/WO2014207556A1/en not_active Ceased
- 2014-06-24 LT LTEP14818523.4T patent/LT3013351T/lt unknown
- 2014-06-24 MY MYPI2015704731A patent/MY182232A/en unknown
- 2014-06-24 DK DK14818523.4T patent/DK3013351T3/da active
- 2014-06-24 HU HUE14818523A patent/HUE046873T2/hu unknown
- 2014-06-24 SG SG11201510490VA patent/SG11201510490VA/en unknown
- 2014-06-24 US US14/313,264 patent/US9221872B2/en active Active
- 2014-06-24 PL PL14818523T patent/PL3013351T3/pl unknown
- 2014-06-24 MX MX2015017609A patent/MX366341B/es active IP Right Grant
- 2014-06-24 SI SI201431451T patent/SI3013351T1/sl unknown
- 2014-06-24 ES ES14818523T patent/ES2765300T3/es active Active
- 2014-06-24 RS RS20191687A patent/RS60180B1/sr unknown
- 2014-06-24 KR KR1020157036784A patent/KR102247493B1/ko active Active
- 2014-06-24 CN CN201480035471.4A patent/CN105324121A/zh active Pending
-
2015
- 2015-12-21 IL IL24326615A patent/IL243266B/en active IP Right Grant
- 2015-12-22 CL CL2015003704A patent/CL2015003704A1/es unknown
- 2015-12-22 PH PH12015502855A patent/PH12015502855B1/en unknown
-
2016
- 2016-01-06 ZA ZA2016/00089A patent/ZA201600089B/en unknown
-
2019
- 2019-12-23 CY CY20191101352T patent/CY1122523T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502855A1 (en) | Peptides and petidomimetics in combination uses and treatments for cancer patient subpopulations | |
| ZA201802966B (en) | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | |
| PH12015501576A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| SG10201902380SA (en) | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases | |
| PH12014500248B1 (en) | Treatment of breast cancer | |
| EP4272757A3 (en) | Modified nk-92 cells for treating cancer | |
| CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
| MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
| AR082340A1 (es) | Metodos y composiciones para la terapia del cancer de higado | |
| WO2014164704A3 (en) | Compounds and compositions for the treatment of cancer | |
| AU2015279834A8 (en) | Use of peptides that block metadherin-SND1 interaction as treatment for cancer | |
| EA201491699A1 (ru) | Лечение рака ингибиторами tor киназы | |
| MX377618B (es) | Métodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing. | |
| NZ627480A (en) | Inhibitors of iap | |
| SG10201902568YA (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
| EA201492187A1 (ru) | Способы лечения солидных опухолей с использованием кофермента q10 | |
| PH12015500867A1 (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| EA201690376A1 (ru) | Ингибиторы дезоксицитидинкиназы | |
| PH12021550035A1 (en) | Combination therapy | |
| MX359337B (es) | Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer. | |
| PH12016000355B1 (en) | Use of xanthophylls for the treatment of cancers | |
| UA78354U (ru) | Способ лечения базально-клеточного рака кожи | |
| NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
| EA201892813A1 (ru) | Иммунотерапия рака | |
| NZ748422A (en) | Heterocyclic glutaminase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |